



NUTRITION INSIGHT

Fat Matters: Quality as well as Quantity

The rise of obesity in America in the last decade of the twentieth century has led to an explosion of research on metabolic consequences of excess adipose tissue. Diet fads that focus on either low-fat foods or low-carbohydrate (and thus high-fat) foods have prompted many studies of the metabolic consequences of dietary fat levels. Remarkably, much of this research has completely ignored the composition of fat and focused only on dietary amount, implying that the composition is unimportant. Many papers, including ones published in highly ranked research journals, report animal studies in which one group is fed a high-fat diet of unspecified composition that induces overeating and obesity and a control group is fed a standard rodent diet that contains a lower amount of fat, again of unspecified and almost certainly different composition.

That so little attention would be given to the composition of the dietary fat is remarkable in light of the large number of human and animal studies showing that dietary fatty acid composition has a profound influence on many aspects of metabolism. Detailed studies in humans and experimental animals, conducted in the 1950s and since, have shown that each fatty acid has unique but overlapping sets of metabolic properties (Warden and Fisler, 2008).

Could changes in dietary fatty acid composition have a role in the obesity epidemic? Do some fats adversely affect human health more than others? Alternatively, does obesity so overwhelm metabolism that the role of fat composition becomes much less significant? Whatever the answer, the issue cannot be overlooked.

The fatty acids consumed by Americans changed dramatically in the twentieth century. Seed oils such as soy, corn, and canola oils were rare before the industrial revolution of the 1800s because they require mechanical crushing or solvent extraction for efficient production. Fruit oils such as olive and palm oils, along with rendered animal fat (lard and tallow), were more widely used. The high-quality taste and low cost of seed oils drove a rise in seed

oil production throughout the twentieth century. Today, soybean oil accounts for a staggering 20% of calories consumed by Americans, in the form of mayonnaise, deep frying fat, salad dressings, margarine, nondairy coffee creamers, snack foods, and sandwich spreads. It may be found in any food with an ingredient list that refers generically to “vegetable oil.”

The application of conventional and modern molecular methods (genetically modified) to engineer fatty acid composition of various food oils is resulting in the introduction of oils with modified fatty acid content into the food supply. A notable example is the genetic modification of soybeans to produce oils high in oleic acid. High oleic soy oil was developed to replace the use of *trans* fatty acid-rich hydrogenated fats for deep frying and other purposes for which an oil with high oxidative stability is needed. The high oleic soybean oil was generated by downregulating expression of the fatty acid desaturase gene that encodes the enzyme that converts monounsaturated oleic acid to the polyunsaturated linoleic acid. The oil from these soybeans contains about 80% oleic acid, compared to 25% for conventional soybean oil. At the same time, it contains less than 9% linoleic acid compared to 54% in conventional soybean oil, and less α -linolenic acid, 3% compared to 7% in conventional soybean oil. Commercial production of these high oleic soybeans was approved in North American countries in 2009–2010. Further modification of the fatty acid composition (e.g., increasing the α -linolenic acid content) is under development. Similarly, high oleic acid peanuts, with only 3% linoleic acid, are already on the consumer market in Australia as peanut butter and peanut-containing snacks. These current and upcoming changes to the fatty acid composition of the food supply will result in a major change, once again, in the fatty acid composition of fats in our diets and, with this change, we will likely see physiological consequences related to fatty acid composition rather than amount of fat.

16; 15 → 19). Repeated many times for PUFAs, these changes in bond position number when counted from the carboxyl carbon make it difficult to track double bonds and, more importantly, fatty acids that are derived from one another.

A solution is to number double bonds from the other end of the molecule, taking advantage of the fact that mammals cannot insert double bonds into the methyl end portion of the PUFA chain. Two conventions that are routinely used, which are effectively identical, are the IUPAC (International Union of Pure and Applied Chemistry) “n minus” convention and the *omega* convention. Examples of these notations are shown in Figure 6-3 for α -linolenic acid (18:3n-3) and docosahexaenoic acid (22:6n-3).

The IUPAC notation retains a close connection to the systematic organic chemistry notation. The “n” represents the number of carbons in the whole molecule, 18 in the case of α -linolenic acid and 22 in the case of docosahexaenoic

acid. The number of double bonds follows the number of carbons, with the two separated by a colon (e.g., C18:3, or simply 18:3 for α -linolenic acid with three double bonds and 22:6 for docosahexaenoic acid with six double bonds). The location of the double bond closest to the methyl end of the fatty acid is indicated by the “n minus” nomenclature; for α -linolenic acid (18:3n-3), the double bond closest to the methyl end is carbon 18-3 or C15 (i.e., between C15 and C16). For docosahexaenoic acid (22:6n-3), the double bond closest to the methyl end is carbon 22-3 or C19 (i.e., between C19 and C20).

An alternative system called the *omega* notation, proposed by Holman, recognizes that the systematic organic chemistry numbering designates the carbon next to the carboxyl as “ α ,” and labels the last carbon in the acyl chain “ ω .” The first double bond counting from the methyl end of α -linolenic or of docosahexaenoic acid appears at the third carbon and



Applied nutritional investigation

d-Allulose enhances postprandial fat oxidation in healthy humans



Tomonori Kimura M.S.^{a,*}, Akane Kanasaki M.S.^a, Noriko Hayashi M.S.^a,
Takako Yamada M.S.^a, Tetsuo Iida Ph.D.^a, Yasuo Nagata Ph.D.^b,
Kazuhiro Okuma Ph.D.^a

^a Research and Development Department, Matsutani Chemical Industry Co., Ltd., Hyogo, Japan

^b Center for Industry, University and Government Cooperation, Nagasaki University, Nagasaki, Japan

ARTICLE INFO

Article history:

Received 16 February 2017

Accepted 29 June 2017

Keywords:

d-allulose

Rare sugar

Energy expenditure

Fat oxidation

Obesity

d-psicose

ABSTRACT

Objective: d-Allulose, a C-3 epimer of d-fructose, has been reported to decrease body weight and adipose tissue weight in animal studies and is expected to be a potent antiobese sweetener. Our animal study suggested that one of the mechanisms of d-allulose's antiobesity function is an increase in energy expenditure. However, a few studies have thus far explored the underlying mechanism in humans. The aim of this study was to examine the effects of a single ingestion of d-allulose on postprandial energy metabolism in healthy participants.

Methods: Thirteen healthy men and women (mean age of 35.7 ± 2.1 y and body mass index 20.9 ± 0.7 kg/m²) were studied. The study was a randomized, single-blind crossover design with a 1-wk washout period. At 30 min after taking 5 g of d-allulose or 10 mg of aspartame without any sugar as a control, overnight-fasted participants ingested a standardized meal, and energy metabolism was evaluated by a breath-by-breath method. During the experiment, blood was collected and biochemical parameters such as plasma glucose were analyzed.

Results: In the d-allulose-treated group, the area under the curve of fat oxidation was significantly higher than in the control group (10.5 ± 0.4 versus 9.6 ± 0.3 kJ·4 h·kg⁻¹ body weight [BW]; $P < 0.05$), whereas that of carbohydrate oxidation was significantly lower (8.1 ± 0.5 versus 9.2 ± 0.5 kJ·4 h·kg⁻¹ BW; $P < 0.05$). Furthermore, plasma glucose levels were significantly lower, and free fatty acid levels were significantly higher in the d-allulose group than in the control group. No other parameters such as insulin, total cholesterol, or triacylglycerol were modified.

Conclusion: d-Allulose enhances postprandial fat oxidation in healthy humans, indicating that it could be a novel sweetener to control and maintain healthy body weight, probably through enhanced energy metabolism.

© 2017 Elsevier Inc. All rights reserved.

Introduction

Obesity is one of the factors affecting most of the prevalent lifestyle-related health complications such as coronary heart disease, diabetes, and certain types of cancer [1]. Obesity results from an imbalance between energy intake and energy expenditure [1]. However, it is difficult to decrease energy intake from

foods because advanced food technology has introduced energy-packed or energy-hidden foods to the market. Therefore, an increase in energy expenditure has emerged as an attractive strategy for treating or preventing obesity. To this end, food ingredients to burn energy have been explored.

d-Allulose (previously referred to as d-psicose), a C-3 epimer of d-fructose, has 70% sweetness of sucrose, is rarely found in nature, and therefore is referred to as a rare sugar [2]. d-Allulose is also formed from d-fructose during cooking and is present in a very small amount in various foods such as fruit juices and cola drinks [3]. The d-allulose content per 100 g ranges from 0.5 to 130.6 mg; fruit juice contains 21.5 mg and cola drink 38.3 mg. The daily intake of d-allulose is ~0.2 g [3]. About 70% of

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest to declare and have nothing to disclose.

* Corresponding author. Tel.: +81-72-771-2032; fax: +81-72-771-2023.

E-mail address: tomonori-kimura@matsutani.co.jp (T. Kimura).

d-allulose is absorbed and then is excreted via urine. The remaining is not fermented in the large intestine and is excreted into feces [4]. Furthermore, d-allulose is a noncaloric sweetener [5] and has been approved as a Generally Recognized as Safe ingredient by the Food and Drug Administration in 2014.

Studies showed that d-allulose is a potential antidiabetic and antiobese sweetener; 0.2 g/kg of d-allulose decreases absorption of sugar by inhibiting intestinal α -glucosidase in Wistar rats compared with nontreated animals [6]. Intake of 0.2 g/kg of d-allulose activates the translocation of glucokinase from the nucleus to the cytosol in the liver that facilitates glycogen biosynthesis in Wistar and Goto-Kakizaki (type 2 diabetes mellitus [T2DM] model) rats [7]. In healthy humans, a single ingestion of 5 g of d-allulose improves insulin sensitivity after administering maltodextrin [8]. Feeding the 5% d-allulose solution enhances insulin sensitivity in T2DM model Otsuka Long-Evans Tokushima Fatty rats compared with only water [9]. Furthermore, d-allulose decreases body weight and abdominal adipose tissue weight in animal studies [10–13]. The proposed underlying mechanism of d-allulose-induced antiobese action is that it suppresses the activity of hepatic lipogenic enzymes such as fatty acid synthase (FAS) and glucose-6-phosphate dehydrogenase [10,12], augments the hepatic carnitine palmitoyl-transferase activity essential for fatty acid oxidation [13], and increases energy expenditure [12,13].

However, no studies thus far have been done to see if and how d-allulose modifies energy metabolism in humans. Furthermore, to apply d-allulose to a broad range of diet regimens, clinical studies are imperative. We thus investigated the effects of a single ingestion of d-allulose on postprandial energy metabolism in 13 healthy individuals. We measured short-term (4-h) energy metabolism as d-allulose is metabolized and excreted from the body quickly after ingestion [14] and has an immediate effect on lipid metabolism in rats [13]. To our knowledge, the present study showed for the first time that d-allulose increased fat oxidation and decreased carbohydrate oxidation in healthy humans. This result suggests the possibility that d-allulose may help control healthy body weight, partially via enhanced energy metabolism in humans.

Materials and methods

Participants

Thirteen healthy volunteers (five men and eight women) were recruited. Participants were excluded if they were diagnosed with diabetes or metabolic disorders such as cardiovascular diseases. Individuals with a mean age of 35.7 ± 2.1 y and body mass index (BMI) of 20.9 ± 0.7 kg/m² participated in the study. This study was conducted according to the principles of the Declaration of Helsinki and approved by the Ethics Committee of Matsutani Chemical Industry Co., Ltd. (Hyogo, Japan). Written informed consent was obtained from all participants before the experiment.

Test samples

The test sample used in this study was 5 g of d-allulose with >99% purity (Matsutani Chemical Industry Co., Ltd.). As a control, 10 mg of aspartame (Ajinomoto Co., Inc. Tokyo, Japan) was used without any sugar. Each sample was dissolved in 150 mL of water and their sweetness was equivalent.

Experimental design

This was a randomized, single-blind study, and all participants received crossover treatment after a 1-wk washout period. They were asked to avoid overeating and excessive exercise, and consumed a specified evening meal (about 450 kcal containing ~15 g of fat [30% as calorie] and ~30 g of protein [27% as calorie]). The specified evening meal was given before 2100 so that participants fasted at least 12 h before the experiment.

Participants first took the beverage containing d-allulose or aspartame, and then 30 min later, ingested a standardized breakfast over 10 min. Breakfast consisted of 200 g of cooked rice, 166 g of hamburger steak, and 150 mL of water, which provided 571 kcal containing 61% of calories as carbohydrate, 25% as fat, and 14% as protein. After breakfast, energy metabolism was evaluated by a breath-by-breath method, blood was collected, and biochemical parameters such as plasma glucose were analyzed.

Energy metabolism assessment

Energy metabolism was measured by a breath-by-breath method using a respiratory gas analyzer (AE-310 S; Minato Medical Science Co., Ltd. Osaka, Japan). After breakfast, participants sat quietly with a face mask on, and then energy metabolism was measured for 6 min intervals every 30 min throughout the experiment (4 h). Data obtained during the last 3 min of each measurement period were analyzed and averaged by calculating minute by minute. Assuming that protein oxidation accounts for 15% energy expenditure, resting energy expenditure (REE), carbohydrate energy expenditure (CEE), and fat energy expenditure (FEE) were calculated by the method of Elia and Livesey [15], and expressed as per body weight (BW). Respiratory quotient (RQ) also was analyzed. The area under the curve (AUC) was calculated as the area between the curve and the x axis ($y = 0$) [16].

Plasma metabolite analyses

During the measurement of energy metabolism, blood was collected, and the levels of plasma glucose, insulin, total cholesterol (TC), triacylglycerol (TG), and free fatty acids (FFA) were analyzed. Changes in parameters such as glucose and insulin were calculated by subtracting values at each time point from baseline values (Δ).

Statistical analysis

All of the values are expressed as mean \pm SEM. Two-way analysis of variance was used to analyze time-course changes (treatment group \times time). When a significant effect of each group or interaction was found, a paired Student's *t* test was carried out at each time point. $P < 0.05$ was considered statistically significant. Statistics were determined by using SPSS 13.0 J (IBM Co., Armonk, NY, USA).

Results

Energy metabolic parameters

No significant difference in REE between the two groups was demonstrated (Fig. 1A). However, ingesting d-allulose caused a significant increase in FEE at 90 min compared with the control group (Fig. 1C). CEE and RQ were significantly lower in the d-allulose group than in the control group; CEE at 90, 210, and 240 min (Fig. 1B), and RQ at 240 min (Fig. 1D) were lower. The AUC of REE, CEE, and FEE for 4 h after a meal are summarized in Figure 1E. The AUC of FEE was significantly increased (10.5 ± 0.4 versus 9.6 ± 0.3 kJ \cdot 4 h \cdot kg⁻¹ BW; $P < 0.05$), whereas that of CEE was significantly decreased (8.1 ± 0.5 versus 9.2 ± 0.5 kJ \cdot 4 h \cdot kg⁻¹ BW; $P < 0.05$) in the d-allulose group compared with the control group (Fig. 1E).

Plasma metabolite parameters

In the d-allulose-treated group, Δ plasma glucose at 90 min (Fig. 2A) was significantly lower. After a single ingestion of d-allulose, FFA was kept at higher levels compared with the control with the difference at 180 min and thereafter being significant (Fig. 2E). There were no differences in the levels of insulin, TC, and TG between two groups (Fig. 2B–D).

Discussion

In previous animal studies, d-allulose decreased body weight and abdominal adipose tissue weight [10–13], suggesting that the 3% to 5% d-allulose diets may have antiobese action. The




Fig. 1. Effects of d-allulose on various parameters in energy metabolism in humans: (A) REE, (B) CEE, (C) FEE, (D) RQ, and (E) the AUC of REE, CEE, and FEE. Data expressed as mean \pm SEM ($n = 13$ in each group) by a paired Student's *t* test. AUC, area under the curve; CEE, carbohydrate energy expenditure; FEE, fat energy expenditure; REE, resting energy expenditure; RQ, respiratory quotient. *Significant differences at $P < 0.05$. †Significant differences at $P < 0.01$.

proposed mechanism of d-allulose-induced antiobese action is that d-allulose suppresses hepatic lipogenesis [10,12] and augments hepatic fatty acid oxidation, resulting in enhanced energy expenditure [13]. In partial agreement with previous animal studies [13], the present study demonstrated that a single ingestion of 5 g d-allulose before a meal significantly enhanced postprandial fat oxidation and spared carbohydrate oxidation compared with the control group. To the best of our knowledge, this is the first study to demonstrate the potential of d-allulose in controlling and maintaining healthy body weight through energy metabolism.

With regard to the mechanisms of d-allulose's antiobese action, intestinal events may be suggested. d-Allulose is known to have an inhibitory action of α -glucosidase, which breaks down sucrose into glucose in the small intestine [6]. It is reported that a single ingestion of coffee polyphenols (CPP), an α -glucosidase inhibitor, also exhibited higher postprandial fat oxidation and energy expenditure, and lowered carbohydrate oxidation, resulting in decreased RQ [17–19]. Because glucose metabolism is known to regulate energy metabolism via glycolysis and fatty acid synthesis, decreased absorption of glucose may be in part responsible for an increase in fat oxidation and a decrease in carbohydrate oxidation.

Although the levels of insulin did not decrease in the present study, d-allulose is reported to improve glucose tolerance and to enhance insulin sensitivity in humans [8]. Increases in insulin have been known to reduce fatty acid oxidation accompanied with reduced levels of plasma FFA [20]. However, FFA levels were augmented by d-allulose concomitantly with upregulated fat oxidation and downregulated carbohydrate oxidation in the present study (Fig. 2E), thus indicating that insulin may be involved in d-allulose-induced fat oxidation. Increased insulin sensitivity could shift an energy source toward fat.

Ochiai et al. found that d-allulose increases glycogen contents in the liver, which may be due to hepatic glucokinase [12]. Glucokinase activity in the liver is a key step of glycolysis, glycogen synthesis, and pentose pathway [21]. Furthermore, translocation of glucokinase from the nucleus to the cytoplasm is reported to be impaired in T2DM [22], implying an important role for glucokinase in glucose metabolism. Our previous study showed that d-allulose promotes glucokinase translocation in the liver, activating glucokinase activity [7]. Thus, it is assumed that d-allulose activates glucokinase activity and stimulates glycogen synthesis, consequently sparing glucose. However, contradictory results on the role of glucokinase in energy metabolism have been reported. Overexpression of glucokinase




Fig. 2. Effects of d-allulose on biological parameters in humans: (A) Δ plasma glucose, (B) Δ plasma insulin, (C) plasma TC, (D) plasma TG, and (E) plasma FFAs. Data expressed as mean \pm SEM ($n = 13$ in each group) by a paired Student t test. FFA, free fatty acid; TC, total cholesterol; TG, triacylglycerol. *Significant differences at $P < 0.05$. †Significant differences at $P < 0.01$.

in the liver increases energy expenditure, probably through effects secondary to lowering plasma insulin and glucose [23], whereas hepatic glucokinase expression suppresses brown adipose tissue thermogenesis via neural signals, which is associated with downregulated energy metabolism [24]. Thus, further studies using animal model and humans with impaired glucose tolerance or diabetes are required to see whether and how glucose metabolism modulated by d-allulose plays a role in regulating lipid and energy metabolism.

In the present study, FFA was kept at higher levels after ingestion of d-allulose throughout the experiment (Fig. 2E), indicating that d-allulose elevated a mobilization of fat from adipose tissue as a fuel. This result may support previous studies in which d-allulose decreases adipose tissue weight and upregulates fat oxidation in rats via proliferator-activated receptor α [12,13]. However, it is unclear where in the body energy expenditure is enhanced or precisely what triggers an increase in energy metabolism.

There are some limitations in the present study. First, the measurement was carried out only for 4 h. d-Allulose is metabolized and excreted from the body quickly after ingestion [14], and it has an immediate effect on lipid metabolism in rats [13]. A metabolomics approach recently demonstrated that acute intake

of sugar-sweetened beverages alters dietary biomarkers within several hours [25], indicating that carbohydrate in beverages has the potential to modify metabolism in the short term. Thus, a 4-h measurement of some parameters may be appropriate to see differences. Second, in the present study, postprandial energy expenditure showed no significant difference, in contrast to the result showing that in rats fed d-allulose over a long-term period, postprandial energy expenditure was significantly increased during the latter half of the dark period [12] or during the late of the light period [13]. The contradictory results also were observed in CPP-fed mice and humans [17,18]. The similar discrepancy may be due to experimental conditions, a single ingestion versus chronic feeding of d-allulose and animal study versus human study. It is thus necessary to do long-term studies to investigate whether and, if so, how energy expenditure might be increased by d-allulose in humans. Finally, in the present study, participants were not stratified by sex because of a relatively small number of men. Sex difference in energy expenditure may exist because body fat size is generally greater in women than in men and the mobilization of fatty acid from adipose tissue may be influenced by plasma hormones such as estrogen [26]. Previous studies, however, have revealed that feeding d-allulose causes an increase in energy expenditure and fat oxidation in male rats [12,13]. BMI

of the study participants was within a low range (21.7 ± 1.4 in male versus 20.4 ± 0.9 kg/m² in female). Therefore, sex difference in fat size between male and female participants may not mislead to our conclusion. However, further studies using a large number of male and female participants with or without are needed to confirm the antiobese action of d-allulose.

We investigated the effect of d-allulose on energy metabolism only in healthy individuals, which could not be extrapolated to those with various diseases such as diabetes and obesity. Given that high-fructose corn syrup-enriched beverages have been used in the food industry for many years and the noncaloric value of d-allulose at a low dose has been reported, d-allulose may be applied to a broad range of diet regimens. Further studies would be imperative to see the effects of d-allulose on energy and lipid metabolism in humans under different conditions.

Conclusion

At a low dose, d-allulose enhanced postprandial fat oxidation and decreased carbohydrate oxidation in healthy humans. This indicates that d-allulose has the potential to be an antiobese sweetener in humans. Further studies in humans are needed to confirm these effects using a large number of individuals with various diseases such as diabetes and obesity and feeding d-allulose over a long-term period.

Acknowledgments

The authors acknowledge the volunteers who participated in this study.

References

- [1] Crowley VE, Yeo GS, O'Rahilly S. Obesity therapy: altering the energy intake-and-expenditure balance sheet. *Nat Rev Drug Discov* 2002;1:276–86.
- [2] Hossain A, Yamaguchi F, Matsuo T, Tsukamoto I, Toyoda Y, Ogawa M, et al. Rare sugar D-allulose: potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus. *Pharmacol Ther* 2015;155:49–59.
- [3] Oshima H, Kimura I, Izumori K. Psicose contents in various food products and its origin. *Food Sci Technol Res* 2006;12:137–43.
- [4] Iida T, Hayashi N, Yamada T, Yoshikawa Y, Miyazato S, Kishimoto Y, et al. Failure of D-psicose absorbed in the small intestine to metabolize into energy and its low large intestinal fermentability in humans. *Metabolism* 2010;59:206–14.
- [5] Matsuo T, Suzuki H, Hashiguchi M, Izumori K. D-psicose is a rare sugar that provides no energy to growing rats. *J Nutr Sci Vitaminol* 2002;48:77–80.
- [6] Matsuo T, Izumori K. D-psicose inhibits intestinal α -glucosidase and suppresses glycemic response after carbohydrate ingestion in rats. *Tech Bull Fac Agr Kagawa Univ* 2006;58:27–32.
- [7] Toyoda Y, Mori S, Umemura N, Nimura Y, Inoue H, Hata T. Suppression of blood glucose levels by D-psicose in glucose tolerance test in diabetic rats. *Jpn Pharmacol Ther* 2010;38:261–9.
- [8] Iida T, Kishimoto Y, Yoshikawa Y, Hayashi N, Okuma K, Tohi M, et al. Acute-D-psicose administration decreases the glycemic responses to an oral maltodextrin tolerance test in normal adults. *J Nutr Sci Vitaminol* 2008;54:511–4.
- [9] Hossain A, Yamaguchi F, Hirose K, Matsunaga T, Sui L, Hirata Y, et al. Rare sugar D-psicose prevents progression and development of diabetes in T2 DM model Otsuka Long-Evans Tokushima Fatty rats. *Drug Des Devel Ther* 2015;9:525–35.
- [10] Matsuo T, Baba Y, Hashiguchi M, Takeshita K, Izumori K, Suzuki H. Dietary D-psicose, a C-3 epimer of D-fructose, suppresses the activity of hepatic lipogenic enzymes in rats. *Asia Pac J Clin Nutr* 2001;10:233–7.
- [11] Matsuo T, Baba Y, Hashiguchi M, Takeshita K, Izumori K, Suzuki H. Less body fat accumulation with D-psicose diet versus D-fructose diet. *J Clin Biochem Nutr* 2001;30:55–65.
- [12] Ochiai M, Onishi K, Yamada T, Iida T, Matsuo T. D-Psicose increases energy expenditure and decreases body fat accumulation in rats fed a high-sucrose diet. *Int J Food Sci Nutr* 2014;65:245–50.
- [13] Nagata Y, Kanasaki Y, Tamaru S, Tanaka K. d-Psicose, an epimer of d-fructose, favorably alters lipid metabolism in Sprague-Dawley rats. *J Agric Food Chem* 2015;63:3168–76.
- [14] Tsukamoto I, Hossain A, Yamaguchi F, Hirata Y, Dong Y, Kamitori K, et al. Intestinal absorption, organ distribution, and urinary excretion of the rare sugar d-psicose. *Drug Des Devel Ther* 2014;17:1955–64.
- [15] Elia M, Livesey G. Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. *World Rev Nutr Diet* 1992;70:68–131.
- [16] Wolever TM, Jenkins DJ, Jenkins AL, Josse RG. The glycemic index: methodology and clinical implications. *Am J Clin Nutr* 1991;54:846–54.
- [17] Murase T, Yokoi Y, Misawa K, Ominami H, Suzuki Y, Shibuya Y, et al. Coffee polyphenols modulate whole-body substrate oxidation and suppress postprandial hyperglycaemia, hyperinsulinaemia and hyperlipidaemia. *Br J Nutr* 2012;107:1757–65.
- [18] Soga S, Ota N, Shimotoyodome A. Stimulation of postprandial fat utilization in healthy humans by daily consumption of chlorogenic acids. *Biosci Biotechnol Biochem* 2013;77:1633–6.
- [19] Murase T, Misawa K, Minegishi Y, Aoki M, Ominami H, Suzuki Y, et al. Coffee polyphenols suppress diet-induced body fat accumulation by down-regulating SREBP-1 c and related molecules in C57 BL/6 J mice. *Am J Physiol Endocrinol Metab* 2011;300:E122–33.
- [20] Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. *J Lipid Res* 1994;35:177–93.
- [21] Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. *Diabetes Metab* 2004;30:398–408.
- [22] Toyoda Y, Ito Y, Tanigawa K, Miwa I. Impairment of glucokinase translocation in cultured hepatocytes from OLETF and GK rats, animal models of type 2 diabetes. *Arch Histol Cytol* 2000;63:243–8.
- [23] Wu C, Kang JE, Peng LJ, Li H, Khan SA, Hillard CJ, et al. Enhancing hepatic glycolysis reduces obesity: differential effects on lipogenesis depend on site of glycolytic modulation. *Cell Metab* 2005;2:131–40.
- [24] Tsukita S, Yamada T, Uno K, Takahashi K, Kaneko K, Ishigaki Y, et al. Hepatic glucokinase modulates obesity predisposition by regulating BAT thermogenesis via neural signals. *Cell Metab* 2012;16:825–32.
- [25] Gibbons H, McNulty BA, Nugent AP, Walton J, Flynn A, Gibney MJ, et al. A metabolomics approach to the identification of biomarkers of sugar-sweetened beverage intake. *Am J Clin Nutr* 2015;101:471–7.
- [26] Halkes CJ, van Dijk H, Verseyden C, de Jaegere PP, Plokker HW, Meijssen S, et al. Gender differences in postprandial ketone bodies in normolipidemic subjects and in untreated patients with familial combined hyperlipidemia. *Arterioscler Thromb Vasc Biol* 2003;23:1875–80.